Table 5e. Significantly down-regulated E treatment

Table 5a. Significantly down regulated genes for Cx10 treatment

Table 5b. Significantly up regulated genes for Cx10 treatment

Table 5c. Significantly down-regulated Gb treatment

Table 5d. Significantly up-regulated Gb treatment

Table 5f. Significantly up-regulated E treatment

Table 1 Selection of core-up-regulated genes in human MDDCs in response to ALVAC

Table 1: Genes up-regulated or down-regulated in human uterine microvascular endothelial cells following 10L9 mol/L E2 and/or 10L8 mol/L P treatment for 4 h or 24 h. The genes showing a significant >2-fold change in all three independent experiments using cDNA microarray analysis are listed.

Table 1. List of Genes up-regulated following CPT treatment in both U87-MG and DBTRG-05 cells; first 13 genes of the list are DNA-Damage and/or stress-responsive genes and the last 9 are miscellaneous

Table 2. Genes down-regulated following CPT treatment in both U87-MG and DBTRG-05; List consists of DNA metabolism and replication  cell cycle and mitosis  and miscellaneous genes

Supplementary Table 1-AURKA Gene Module; Proliferation gene module; the module was populated by genes being significantly correlated to AURKA  a well-known proliferation-related gene  as determined by a cross-validation strategy in a meta-analytical framework

Supplementary Table 1-CASP3 Gene Module; Apoptosis gene module; the module was populated by genes being significantly correlated to CASP3 a well-known apoptosis-related gene  as determined by a cross-validation strategy in a meta-analytical framework

Supplementary Table 1-ERBB2 Gene Module; HER2-phenoytype gene module; the module was populated by genes being significantly correlated to ERBB2 as determined by a cross-validation strategy in a meta-analytical framework

Supplementary Table 1-ESR1 Gene Module; ER-phenotype gene module; the module was populated by genes being significantly correlated to ESR1 as determined by a cross-validation strategy in a meta-analytical framework